52nd week of 2010 patent applcation highlights part 55 |
Patent application number | Title | Published |
20100331170 | ALKALI METAL SUPER IONIC CONDUCTING CERAMIC - Metal ion conducting ceramic materials are disclosed having characteristics of high ion conductivity for certain alkali and monovalent metal ions at low temperatures, high selectivity for the metal ions, good current efficiency and stability in water and corrosive media under static and electrochemical conditions. The metal ion conducting ceramic materials are fabricated to be deficient in the metal ion. One general formulation of the metal ion conducting ceramic materials is Me | 2010-12-30 |
20100331171 | Layered Sphere Catalysts with High Accessibility Indexes - A process and catalyst for use in the selective hydrogenation of acetylene to ethylene is presented. The catalyst comprises a layered structure, wherein the catalyst has an inner core and an outer layer of active material. The catalyst further includes a metal deposited on the outer layer, and the catalyst is formed such that the catalyst has an accessibility index between 3 and 500. | 2010-12-30 |
20100331172 | CATALYST CARRIER, CATALYST AND PROCESS FOR PRODUCING THE SAME - The present invention provides a catalyst carrier having excellent durability and capable of attaining high catalytic ability without increasing the specific surface area thereof, and a catalyst obtainable by using the catalyst carrier. The catalyst carrier of the present invention comprises a metal oxycarbonitride, preferably the metal contained in the metal oxycarbonitride comprises at least one selected from the group consisting of niobium, tin, indium, platinum, tantalum, zirconium, copper, iron, tungsten, chromium, molybdenum, hafnium, titanium, vanadium, cobalt, manganese, cerium, mercury, plutonium, gold, silver, iridium, palladium, yttrium, ruthenium, lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, and nickel. Moreover, the catalyst of the present invention comprises the catalyst carrier and a catalyst metal supported on the catalyst carrier. | 2010-12-30 |
20100331173 | CATALYTIC CONVERTER SUPPORT BODY - The present invention relates to a catalyst support body ( | 2010-12-30 |
20100331174 | Catalysts for Oxidative Coupling of Hydrocarbons - A catalyst includes: (A) at least one element selected from the group consisting of the Lanthanoid group, Mg, Ca, and the elements of Group 4 of the periodic table (Ti, Zr, and Hf); (B) at least one element selected from the group consisting of the Group 1 elements of Li, Na, K, Rb, Cs, and the elements of Group 3 (including La and Ac) and Groups 5-15 of the periodic table; (C) at least one element selected from the group consisting of the Group 1 elements of Li, Na, K, Rb, Cs, and the elements Ca, Sr, and Ba; and (D) oxygen. | 2010-12-30 |
20100331175 | SELECTIVE HYDROGENATION CATALYST AND THE PREPARATION THEREOF - A selective hydrogenation catalyst, with alumina as carrier, and palladium as active component that distributed on the surface of the carrier in an egg-shell form, characterized in that: provided that the catalyst is weighed 100%, it comprises 0.2-0.5 wt % active component Pd, 2-8 wt % aids lanthanum and/or cerium, and 2-8 wt % alkaline earth metal. The specific surface area of the catalyst is 70-150 m2/g, the pore volume is 0.3-0.6 ml/g, and the crystal form of the carrier may be θ form or θ, α mixed form mainly composed of θ form. The catalyst is suitable for the selective hydrogenation of medium or low distillate oil, especially for the first stage selective hydrogenation of pyrolysis gasoline. The catalyst has good hydrogenation performance, and can keep good hydrogenation activity and stability especially under the condition that the feed contains a small quantity of water, and the content of colloid, arsenic, and diolefin is higher. | 2010-12-30 |
20100331176 | USE OF POROUS METAL-ORGANIC FRAMEWORK MATERIALS FOR COLOR MARKING OF FILTERS - The present invention relates to the use of a porous metal-organic framework material comprising at least one, at least bidentate, organic compound bound to at least one metal ion by coordination, the at least one metal ion, the at least one, at least bidentate, organic compound, or if appropriate a further component, being a coloring component, as sorbent and for permanent color marking of a filter. | 2010-12-30 |
20100331177 | AMORPHOUS SILICA PARTICLES HAVING HIGH ABSORBING CAPABILITIES AND HIGH STRUCTURAL CHARACTERISTICS - The present invention provides amorphous silica particles having high oil absorbency and high structural characteristics, wherein the oil absorbency is hardly decreased even when a high load is applied to the amorphous silica particles. In particular, amorphous silica particles are provided, wherein the maximum value of ΔVp/ΔRp (where Vp is the pore volume [mm | 2010-12-30 |
20100331178 | Method of synthesizing zirconium-loaded fibrous adsorbent materials having phosphoryl groups and removal of objectionable substances using the adsorbents - A method of forming a zirconium-loaded fibrous adsorbent material having phosphoryl groups, the method including: grafting a reactive monomer having phosphoryl groups onto a polymeric substrate; and loading zirconium such that the zirconium-loaded fibrous adsorbent material has a zirconium content in an amount of 4.0 or 4.2 mmol/g. | 2010-12-30 |
20100331179 | ACTIVATED CARBON CRYOGELS AND RELATED METHODS - Carbon cryogels, methods for making the carbon cryogels, methods for storing a gas using the carbon cryogels, and devices for storing and delivering a gas using the carbon cryogels. | 2010-12-30 |
20100331180 | HONEYCOMB BODY WITH STRUCTURED SHEET METAL MATERIAL AND PARTICLE SEPARATOR, CATALYST CARRIER BODY AND MOTOR VEHICLE HAVING THE HONEYCOMB BODY - A honeycomb body includes at least one housing and a honeycomb structure for a waste-gas purification system having at least one sheet metal material. The sheet metal material has elevations in at least one section and an edge contour enclosing the elevations. A portion of the area of the elevations in the at least one section is at least 80%. A particle separator, a catalyst carrier body and a motor vehicle having the honeycomb body are also provided. | 2010-12-30 |
20100331181 | Method for Protecting Cereals From Being Infected By Fungi - Method for protecting cereals from being infected by harmful fungi, wherein the cereals, their seed or the soil is treated with a synergistically active combination comprising
| 2010-12-30 |
20100331182 | HERBICIDAL CONCENTRATE COMPOSITIONS CONTAINING GLYPHOSATE AND DICAMBA SALTS - The mixture of potassium or certain amine salts of glyphosate and dicamba allows the preparation of high-strength liquid compositions containing greater than 300 gae/L of total active ingredient loading if the pH is adjusted between about 6.0 and about 8.0. Compositions are particularly well-suited for herbicidal applications on crops that are resistant or tolerant to both glyphosate and dicamba. | 2010-12-30 |
20100331183 | AGENT FOR IMPROVING GOOD RICE SEEDLING GROWTH - There is provided an agent for improving the growth of seedlings, having effects of raising healthy rice seedlings, such as increase of the tillering number, increase of root weight, enhancement of greenness, and increase of stem thickness. | 2010-12-30 |
20100331184 | LIQUID HERBICIDAL PREPARATIONS - Herbicidal oil dispersions comprising
| 2010-12-30 |
20100331185 | Herbicidal Compositions of Lithium Glyphosate and Adjuvants - Disclosed are herbicidal compositions comprising a lithium salt of glyphosate and one or more surfactants, the surfactant(s) enhancing the herbicidal efficacy of the lithium salt of glyphosate over that of the lithium salt of glyphosate alone. | 2010-12-30 |
20100331186 | EMULSIFIABLE CONCENTRATE COMPOSITION - Disclosed is an emulsifiable concentrate composition characterized by containing not less than 0.5% by weight but not more than 25% by weight of a hydrophobic agrochemically active compound, not less than 5% by weight but not more than 15% by weight of a surfactant, not less than 2% by weight but not more than 60% by weight of an aromatic hydrocarbon solvent, not less than 2% by weight but not more than 60% by weight of an ether compound represented by the following formula (1): R | 2010-12-30 |
20100331187 | FORMULATIONS - The present invention relates to physically stable oil dispersions. It also relates to a method for activating bentones that are designed for use with a low polarity organic systems. It also relates to physically stable oil dispersions comprising said activated bentone. | 2010-12-30 |
20100331188 | DICAMBA HERBICIDE COMPOSITION - A herbicidal composition comprising dicamba in each of the monomethylamine and dimethylamine salts wherein the ratio of monomethylamine:dimethylamine is from 20:1 to 1:1. | 2010-12-30 |
20100331189 | Plant Growth Promoter Utilizing Potato Cyst Nematode - A growth promoter according to the present invention that can be applied to a plant other than solanaceous plants is a plant growth promoter utilizing potato cyst nematodes and contains a fatty acid dialkanolamide represented by the following general formula (1) as a substance that acts on the potato cyst nematodes: | 2010-12-30 |
20100331190 | BENEFIT AGENT DELIVERY COMPOSITIONS - Benefit agent delivery compositions, compositions, packaged products and displays comprising such benefit agent delivery compositions, and processes for making and using such benefit agent delivery compositions, compositions, packaged products and displays. Such compositions have improved deposition and retention properties that may impart improved benefit characteristics to a composition and/or situs. | 2010-12-30 |
20100331191 | SURFACTANT COMPOUNDS - Oligoesters including residues of alk(en)yl succinic anhydrides and polyols having at least 3 OH groups, optionally further esterified with fatty acid residues are surfactants which can be used for emulsifiers or similar uses. The surfactants are usually made from C | 2010-12-30 |
20100331192 | SURFACE DISPLAY OF RECOMBINANT PROTEINS IN LOWER EUKARYOTES - Methods for display of recombinant proteins or protein libraries on the surface of lower eukaryotes such as yeast and filamentous fungi are described. The methods are useful for screening libraries of recombinant proteins in lower eukaryotes to identify particular proteins with desired properties from the array of proteins in the libraries. The methods are particularly useful for constructing and screening antibody libraries in lower eukaryotes. | 2010-12-30 |
20100331193 | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination - Methods are provided for the evolution of proteins of industrial and pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are also disclosed. | 2010-12-30 |
20100331194 | NANOPORE SEQUENCING DEVICES AND METHODS - The invention relates to devices and methods for nanopore sequencing. The invention includes arrays of nanopores having incorporated electronic circuits, for example, in CMOS. In some cases, the arrays of nanopores comprise resistive openings for isolating the electronic signals for improved sequencing. Methods for controlling translocation of through the nanopore are disclosed. | 2010-12-30 |
20100331195 | Sequencing Nucleic Acid Polymers with Electron Microscopy - This invention relates to using an electron microscope to sequence by direct inspection of labeled, stretched DNA. This method will have higher accuracy, lower cost, and longer read length than current DNA sequencing methods. | 2010-12-30 |
20100331196 | ELECTRON BEAM NUCLEIC ACID SEQUENCING - The present invention relates to compositions, methods, and uses for obtaining sequence information from nucleic acid molecules. | 2010-12-30 |
20100331197 | SYSTEM AND METHOD FOR THE CLONAL CULTURE OF EPITHELIAL CELLS AND APPLICATIONS THEREOF - The invention relates to means and methods for evaluating and using the specific properties of a particular epithelial cell present in a biological sample. Accordingly, the invention relates to a system for the culture of epithelial cells, in which at least one clonal culture is sown with a single epithelial cell directly extracted from a biological sample of epithelial tissue. The invention also relates to a method for the culture of epithelial cells, that particularly comprises the production of clonal cultures, each being sown with a distinct and unique epithelial cell directly extracted from a biological sample of epithelial tissue, the evaluation of the cellular growth in the clonal cultures, and advantageously the analysis of the capacity of the cellular material from the clonal cultures to reconstruct a three-dimensional epithelium representative of native tissue. The invention is adapted for the parallel implementation of a very large number of clonal cultures, in particular for making large-scale tests. | 2010-12-30 |
20100331198 | Photo-generated carbohydrate arrays and the rapid identification of pathogen-specific antigens and antibodies - The invention relates to novel photo-generated carbohydrate arrays and methods of their use to detect the presence of one or more agents in a sample. The invention also relates to a high-throughput strategy to facilitate the identification and immunological characterization of pathogen-specific carbohydrates, including those of | 2010-12-30 |
20100331199 | METHOD FOR THE DETECTION AND/OR ENRICHMENT OF ANALYTE PROTEINS AND/OR ANALYTE PEPTIDES FROM A COMPLEX PROTEIN MIXTURE - The present invention relates to a method for the detection and/or enrichment of a large number of different analyte proteins and/or analyte peptides from a sample mixture which includes proteins and/or peptides. The method includes the following steps: a) provision of the sample mixture and, where appropriate, fragmentation of the proteins contained therein into defined peptides, b) provision of first binding molecules which are specific for a peptide epitope of at least one of the various analyte proteins and/or analyte peptides, whereby the peptide epitope includes up to a maximum of five, preferably two to three, amino acids, c) incubation of the first binding molecules with the sample mixture, and d) detection and/or enrichment of the analyte proteins and/or analyte peptides bound to the first binding molecules. The invention also relates to binding molecules which are specific for the terminal peptide epitope of various peptide analytes, whereby the terminal peptide epitope includes the free NH | 2010-12-30 |
20100331200 | POST TRANSLATIONAL MODIFICATION PATTERN ANALYSIS - This invention relates to methods and apparatus for detecting the pattern of post translational modification in a protein or in a plurality of proteins in a sample. One or more target proteins are subjected to predetermined proteolysis to yield plural peptide fragments comprising potential post translational modification sites. The fragments and the state of such sites are analyzed to yield a post translational pattern for the protein or proteins. | 2010-12-30 |
20100331201 | PROTEIN BIOCHIP FOR THE DIFFERENTIAL SCREENING OF PROTEIN-PROTEIN INTERACTIONS - The present invention relates to a system of protein binders containing at least one protein binder presented in at least one native form and at least one non-native form and its use including a method for discrimination and/or differential screening of suitable protein binders in native and non-native form. | 2010-12-30 |
20100331202 | NANOTUBE STRUCTURES HAVING A SURFACTANT BILAYER INNER WALL COATING - Nanotubes and nanotube array structures comprise (a) a nanotube having an inner wall portion; and (b) a bilayer coating formed on the inner wall portions, with the bilayer coating comprised of surfactants. A secondary compound such as a protein, peptide or nucleic acid may be associated with the bilayer coating. The structures are useful for, among other things, affinity purification, catalysis, and as biochips. | 2010-12-30 |
20100331203 | AROMATASE EXPRESSION PREDICTS SURVIVAL IN WOMEN WITH NON-SMALL CELL LUNG CANCER - The present invention relates to the discovery that the level of aromatase polypeptide expression in non-small cell lung carcinomas can be used for example to provide information useful in prognostic and therapeutic methodologies in women having or suspected of having this cancer. | 2010-12-30 |
20100331204 | METHODS AND SYSTEMS FOR ENRICHMENT OF TARGET GENOMIC SEQUENCES - The present invention provides methods and systems for targeted nucleic acid sequence enrichment in a sample. In particular, the present invention provides for enriching for targeted nucleic acid sequences during hybridizations in hybridization assays by first depleting non-target nucleic acid sequences. | 2010-12-30 |
20100331205 | Method and Apparatus for the Identification and Handling of Particles - The present invention refers to the optimised selection and isolation, within a respective population, of elements of interest and/or utility for a series of subsequent operations. The invention concerns a method comprising the phases of: a) identifying, for each particle, at least one of a plurality of characteristic parameters; b) selecting the particles of interest, comparing for each of these the at least one parameter with a respective reference parameter. It furthermore comprises the phases of c) storing, for each of said particles, the at least one parameter identified; d) processing the value of a function of said stored parameter, associating the function with a criterion for selection of the particles of interest chosen from a group of possible selection criteria; e) establishing for each particle a threshold criterion to be used as reference parameter. The threshold criterion is established on a time by time basis according to the result of the above processing. | 2010-12-30 |
20100331206 | COMPOSITIONS AND METHODS FOR EARLY PREGNANCY DIAGNOSIS - Pregnancy-associated glycoproteins (PAGs) are structurally related to the pepsins, thought to be restricted to the hoofed (ungulate) mammals and characterized by being expressed specifically in the outer epithelial cell layer (chorion/trophectoderm) of the placenta. By cloning expressed genes from ovine and bovine placental cDNA libraries, the inventors estimate that cattle, sheep, and most probably all ruminant Artiodactyla, possess possibly 100 or more PAG genes, many of which are placentally expressed. The PAGs are highly diverse in sequence, with regions of hypervariability confined largely to surface-exposed loops. Selected PAG that are products of the invasive binucleate cells, expressed highly in early pregnancy at the time of trophoblast invasion and expressed weakly, if at all, in late gestation are useful in the early diagnosis of pregnancy. In a preferred embodiment, the invention relates to immunoassays for detecting these PAGs. | 2010-12-30 |
20100331207 | METHODS OF DETECTING NUCLEIC ACID WITH MICROARRAY AND PROGRAM PRODUCT FOR USE IN MICROARRAY DATA ANALYSIS - The invention provides a method of detecting, with a microarray, a target nucleic acid containing a base sequence to which a nucleic acid-binding protein binds, obtaining a signal from a correction probe not containing any sequence complementary to the base sequence to which the nucleic acid-binding protein binds for being used as a background to correct a signal obtained from a detection probe hybridizing to the target nucleic acid, as well as a computer program product for enabling a computer to detect, with a microarray, a target nucleic acid containing a base sequence to which a nucleic acid-binding protein binds. | 2010-12-30 |
20100331208 | Cell Display Of Antibody Libraries - The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics. | 2010-12-30 |
20100331209 | MARKERS AND METHODS FOR ASSESSING AND TREATING SEVERE OR PERSISTANT ASTHMA AND TNF RELATED DISORDERS - A method for assessment of the suitability of and/or effectiveness of a target therapy for a TNF-mediated-related disorder, such as severe or persistent asthma, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes corresponding to contacting the sample with a panel of nucleic acid segments consisting of at least a portion of at least one member from the group consisting of the nucleotide sequences corresponding to at least one of TNFRSF1A SNP rs4149581 (SEQ ID NO:1), TNFRSF1 B SNP rs3766730 (SEQ ID NO:2) or TNFRSFI B SNP rs590977 (SEQ ID NO:3) SNPs which results in a determination that one or more of said SNPs in a sample are in linkage disequilibrium (LD). The method enables identification of the effectiveness of target therapies prior to or after starting a patient on such therapies. | 2010-12-30 |
20100331210 | METHODS AND SYSTEMS FOR EVALUATING THE SENSITIVITY OR RESISTANCE OF TUMOR SPECIMENS TO CHEMOTHERAPEUTIC AGENTS - The present invention provides methods, systems, and kits for evaluating the sensitivity and/or resistance of tumor specimens to one or a combination of chemotherapeutic agents. Particularly, the invention provides malignant cell gene signatures that are predictive of a tumor's response to candidate chemotherapeutic regimens. | 2010-12-30 |
20100331211 | METHOD FOR REAL-TIME DETECTION OF MICROORGANISMS IN A LIQUID CULTURE MEDIUM USING CELLULAR LYSIS - The present invention relates to a method for detecting at least one target microorganism that may be present in a sample, comprising the steps of:
| 2010-12-30 |
20100331212 | METHODS AND SYSTEMS FOR MONITORING MULTIPLE OPTICAL SIGNALS FROM A SINGLE SOURCE - Methods and systems are described for determining information about template sequences by simultaneously providing excitation over time to a plurality of confined sources on a substrate, each confined source carrying out a template mediated addition of nucleotides with a polymerase enzyme. The nucleotides have different labels, each with a different emission wavelength profile. Optical elements direct optical signals from the different NTPs within each optical confinement to different detector locations. Observing the optical signals over time allows for obtaining sequence information about the template nucleic acids. | 2010-12-30 |
20100331213 | MICROPARTICLES WITH ENHANCED COVALENT BINDING CAPACITY AND THEIR USES - A polyelectrolyte having multiple exposed functional groups, each such group being capable of covalently bonding to a molecule, is immobilized on a surface for the purpose of bonding to a biomolecule. The biomolecule can be, for example, a nucleic acid, e.g., an amine functionalized oligonucleotide. The polyelectrolyte can include, e.g., BSA (Bovine Serum Albumin) which is bound to a functionalized surface using a covalent immobilization strategy, e.g., reaction with the surface of a tosyl-activated microparticle. Following such reaction, exposed reactive functional groups on the protein, such as amine, carboxyl, thiol, hydroxyl groups can further be utilized to covalently couple the oligonucleotide of interest using suitable chemistry. | 2010-12-30 |
20100331214 | siRNA Targeting Survivin - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Through these methodologies, one can select siRNA that target genes, including surviving. | 2010-12-30 |
20100331215 | Peptide Synthesis Apparatuses - Methods, apparatus, systems, computer programs and computing devices related to biologically assembling and/or synthesizing peptides and/or proteins are disclosed. | 2010-12-30 |
20100331216 | CELL CULTURE METHOD - To provide a cell culture method capable of sustaining in-vivo functions for a long time by suppressing dedifferentiation. A cell culture method in accordance with the present invention is to culture cells in a multi-layered state in a minute partitioned space and to obtain a tissue structure having a function resembling an in-vivo function. When the cells are mammary gland epithelial cells, a hollow acinus-like structure can be formed. The minute partitioned space is particularly preferably a micro container in a cell culture container having a plurality of such micro containers on the surface. | 2010-12-30 |
20100331217 | SUBSTRATE PREPARATION PROCESS - The present invention provides novel processes for the large scale preparation of arrays of polymer sequences wherein each array includes a plurality of different, positionally distinct polymer sequences having known monomer sequences. The methods of the invention combine high throughput process steps with high resolution photolithographic techniques in the manufacture of polymer arrays. | 2010-12-30 |
20100331218 | PHOTOACID GENERATORS FOR THE SYNTHESIS OF OLIGO-DNA IN A POLYMER MATRIX - Compounds represented by the following structural formulas can be used as photoacid generators: | 2010-12-30 |
20100331219 | TEMPERATURE CONTROLLER FOR STRUCTURE - A temperature controller for controlling temperature of a first structure having a first flat face comprises a second structure having a second flat face for planar contact with the first flat face, a pressure-applying means for pressing the first structure, a second supporting means for supporting the second structure to be capable of changing inclination of the second flat face, a first supporting means for supporting the first structure by contact with a portion of the first structure other than the first flat face, and a temperature-controlling means, wherein the first structure is supported by pressing the first structure by the pressure-applying means, and the second structure is brought into contact with the temperature-controlling means with interposition of the second supporting means. | 2010-12-30 |
20100331220 | ACOUSTIC DEVICE - There is disclosed an acoustic device for manipulation of fluid samples including fluid samples comprising particles characterised in that it comprises a flexible member, a sound wave generator for generating a sound wave and a sound wave coupler for coupling the sound wave from the generator into the flexible member, in which the device, flexible member and the coupler are adapted to excite a predetermined acoustic mode of pure resonant vibration in the flexible member at a predetermined frequency of the sound wave. | 2010-12-30 |
20100331221 | Drilling fluid additive containing heated syrup solids - A drilling fluid additive is provided and the additive consist of: syrup solids which are heated to evaporate water and then admixed with a liquid medium, and the syrup solids are derived from a group consisting essentially of agave syrup, barley syrup, sugar syrup, beets syrup, birch syrup, rice syrup, cane syrup, chocolate syrup, coconut syrup, corn syrup, date syrup, fruit syrup, golden syrup, high fructose corn syrup, karo syrup, citrus fruit syrup, maple syrup, molasses, Muscavado syrup, palm syrup, rice syrup, sorghum syrup, Turbinado syrup, vanilla syrup and mixtures and blends thereof. | 2010-12-30 |
20100331222 | PROCESS FOR PRODUCING CELLULOSE BEADS FROM SOLUTIONS OF CELLULOSE IN IONIC LIQUID - Process for producing cellulose beads or lignocellulose beads, wherein cellulose or lignocellulose is dissolved in a solvent which comprises more than 50% by weight of the symmetrical imidazolium compound of the formula I below | 2010-12-30 |
20100331223 | Acidic Viscosity Enhancer for Viscoelastic Surfactant Fluids - The invention discloses method of treating a subterranean formation of a well bore, the method comprising: providing a treatment fluid comprising: an aqueous base fluid; a viscosity enhancer; and a viscoelastic surfactant, wherein the enhancer is acid in the aqueous base fluid and co-operates with the viscoelastic surfactant to enhance viscosity compared to viscoelastic surfactant alone in the aqueous base fluid; and introducing the treatment fluid into the well bore. | 2010-12-30 |
20100331224 | Lubricating Oil Compositions Comprising A Molybdenum Compound And A Zinc Dialkyldithiophosphate - Provided herein are lubricating oil compositions comprising a major amount of a base oil, at least one oil-soluble molybdenum compound and a zinc dialkyldithiophosphate compound, wherein the molybdenum content derived from the molybdenum compound is at least 10 ppm based on the total weight of the lubricating oil composition and the phosphorus content derived from the zinc dialkyldithiophosphate compound is about 200 to 500 ppm based on the total weight of the lubricating oil composition. The lubricating oil composition can further comprise at least one additive. Methods of making and using the lubricating oil compositions are also described. | 2010-12-30 |
20100331225 | Multiple Use Fabric Conditioning Composition with Aminosilicone - Multiple use fabric conditioning compositions comprising aminosilicones are disclosed. The disclosed compositions are capable of delivering a benefit to a fabric over multiple cycles. Such benefits may include removal of wrinkles, prevention of wrinkles, fabric softness, improved fabric feel, garment shape retention, garment shape recovery, elasticity, ease-of-ironing, perfume benefits, anti-pilling, or combinations thereof. | 2010-12-30 |
20100331226 | Damage-Free High Efficiency Particle Removal Clean - A system, method and an apparatus to remove contaminants from a semiconductor substrate surface includes application of a cleaning material. The cleaning material includes a cleaning solution and a plurality of micron-sized dry polyvinyl particles dispersed in the cleaning solution. The cleaning solution is a single phase polymeric compound that is made of long polymeric chains and exhibits distinct viscoelastic properties. The plurality of micron-sized dry polyvinyl alcohol particles absorb the liquid in the cleaning solution and become uniformly suspended within the cleaning material. The suspended polyvinyl alcohol particles interact with at least some of contaminants on the semiconductor substrate surface to release and remove the contaminants from the substrate surface. The released contaminants are entrapped within the cleaning material and removed with the cleaning material leaving behind a substantially clean substrate surface. | 2010-12-30 |
20100331227 | HYDROGEN PEROXIDE BASED CLEANING, SANITIZING, DEODORIZING AND SCALE INHIBITING SOLUTION - An environmentally friendly hydrogen peroxide cleaning and sanitizing solution is disclosed that may be used for cleaning, deodorizing, sanitizing and scale inhibiting in toilets and urinals in washroom and toilet areas. The solution also has the added benefit of eliminating odours and reducing corrosion in the washroom plumbing. The present cleaning and sanitizing solution consists of distilled water, hydrogen peroxide, a surfactant, a hydrogen peroxide stabilizer, a chelating agent, and corrosion inhibitors. The pH of the cleaning and sanitizing solution is greater than 6.0, and typically about 6.0 to about 8.0. The present cleaning, sanitizing, deodorizing and scale inhibiting solution is distributed to the washroom fixtures by means of refillable pump systems commonly known in the art. | 2010-12-30 |
20100331228 | Use of Alkane Sulfonic Acid For Descaling In the Agri-Food Industry - The present invention relates to the use of alkane sulfonic acid for descaling, and more generally for cleaning vats, casks, and other containers used for the storage, shipping, and handling of meat and early produce, particularly poultry, fruit, and vegetables. The present invention also relates to a composition in gel form including at least one alkane sulfonic acid. | 2010-12-30 |
20100331229 | BLEACHING COMPOSITIONS COMPRISING A PERFUME DELIVERY SYSTEM - Particulate bleaching composition comprising a bleaching system, as a first essential component, which comprises oxygen bleach, a bleach activator and a perfume delivery system. Such perfume delivery system is preferably chosen among an amine reaction product containing perfume or an encapsulated perfume made of starch. | 2010-12-30 |
20100331230 | Composition - A particulate material comprising a bleach catalyst wherein the particles of the bleach catalyst have a coating and the weight ratio of the coating to the bleach catalyst is in the range of from 10-60 wt %. The particulate material exhibits good stability. | 2010-12-30 |
20100331231 | NON-RINSE FABRIC SOFTENER - The invention relates to compositions which are suitable as fabric softeners, particularly for softening fabrics that have been washed with highly concentrated detergents. Said compositions are obtainable by esterification of a C | 2010-12-30 |
20100331232 | Starch-based hydrogel for biomedical applications - A starch-based hydrogel for the controlled delivery of a biologically active agent is described. The hydrogel comprises a dispersed phase, and a dispersion medium consisting substantially of water. The dispersed phase includes a polymeric network comprising a hydrolyzable polymeric substance derived from starch, and a cross-linker. In various embodiments, the polymeric starch-derived network includes amylose, amylopectin, or a combination thereof, or soluble starch. The cross-linker is a molecule having at least two carboxyl moieties. The hyrogel is biocompatible and biodegradable, and suitable for loading with biologically active agents ranging from small molecule therapeutics to macromolecules such as proteins, polysaccharides and nucleic acids. Upon administration to a host animal, the hydrogel biodegrades, releasing as degradation products only naturally-occurring sugar molecules that are non-toxic and non-immunogenic to the host. | 2010-12-30 |
20100331233 | CRYSTAL OF XPA AND ERCC1 COMPLEX AND USES THEREOF - The present invention relates to complexes and crystals of an XPA peptide and an ERCC1 peptide, and structural coordinates of the complex obtained from such crystals. The coordinates are useful for identifying compounds that bind to ERCC1 and inhibit binding of XPA, and thus inhibitors of nucleotide excision repair (NER). The NER inhibitors are used for treating neoplastic diseases, cancer, and hyperproliferative disorders. | 2010-12-30 |
20100331234 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF - Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these aminoalcohol lipidoid compounds, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive lipidoids and polynucleotide have been prepared. The inventive lipidoids may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings. | 2010-12-30 |
20100331235 | Histidine and/or Histidine Derivative for the Treatment of Inflammatory Skin Diseases - Histidine and/or a derivative thereof. In some embodiments, the histidine and/or a derivative thereof is used in maintaining and/or improving barrier function of the skin of a subject. In some embodiments, the histidine and/or a derivative thereof is used for the prevention and/or treatment of an inflammatory skin disease. | 2010-12-30 |
20100331236 | CYCLIC PEPTIDES AS G-PROTEIN COUPLED RECEPTOR ANTAGONISTS - The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions. | 2010-12-30 |
20100331237 | GAG BINDING PROTEINS - A method is provided for introducing a GAG binding site into a protein comprising the steps:
| 2010-12-30 |
20100331238 | Human G protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to MCP-1 expression - The present invention relates to methods of using a G protein-coupled receptor (GPCR) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the GPCR couples to Gi. In certain embodiments, the GPCR is human. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of atherosclerosis and atherosclerotic disease, including coronary artery disease, myocardial infarction, peripheral arterial disease, and ischemic stroke. Agonists of the invention are additionally useful as therapeutic agents for the prevention or treatment of conditions related to MCP-1 expression, including but not limited to rheumatoid arthritis, Crohn's disease, and multiple sclerosis. | 2010-12-30 |
20100331239 | CD14 AND PEPTIDES THEREOF FOR PROTECTION OF CELLS AGAINST CELL DEATH - Provided is a method of using soluble CD14 or peptides derived therefrom for protecting cells from death, specifically from apoptotic cell death. Further provided are compositions including CD14 or CD14 peptides and methods for protecting cells, in particular lymphocytes, from apoptotic cell death. The compositions and methods are relevant, in particular, for the treatment of various immune deficiencies associated, for example, with cell transplantation procedures, autoimmune diseases and infectious diseases such as HIV. | 2010-12-30 |
20100331240 | METHODS FOR PREVENTION AND TREATMENT OF INFECTIONS WITH SUPRAPHYSIOLOGICAL DOSES OF MANNAN-BINDING LECTIN (MBL) AND FICOLIN-MBL FUSION PROTEINS - The present invention provides methods of treatment and/or prevention of infections, for example, viral and bacterial infections, in individuals, wherein the method comprises administering a supraphysiological amount of mannose-binding lectin (MLB) and/or ficolin-MBL fusion protein to an individual afflicted with an infection or at risk of an infection, such as a bacterial or a viral infection. For example, methods for treatment and/or prevention of Ebola virus infection are provided. | 2010-12-30 |
20100331241 | Bacteriocins and Novel Bacterial Strains - Novel bacteriocins and/or the novel lactic acid-producing strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry. | 2010-12-30 |
20100331242 | METHOD OF USING LECTINS FOR PREVENTION AND TREATMENT OF ORAL AND ALIMENTARY TRACT DISORDERS - Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with | 2010-12-30 |
20100331243 | ORGANIC COMPOUNDS AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases. | 2010-12-30 |
20100331244 | PHARMACEUTICAL COMPOSITION, FOOD OR DRINK, AND METHODS RELATED THERETO - A pharmaceutical composition including, as an active ingredient, one of the following proteins (I) and (II): (I) an apoptosis inhibitor of macrophage; and (II) a protein which consists of an amino acid sequence having deletion, substitution, or addition of one or more amino acids in an amino acid sequence of the apoptosis inhibitor of macrophage and having homology to the amino acid sequence of the apoptosis inhibitor of macrophage, and has a function of inhibiting the differentiation of preadipocytes to mature adipocytes and/or a function of inducing lipolysis in the mature adipocytes. | 2010-12-30 |
20100331245 | PEPTIDE YY ANALOGS - The invention provides analogs of PYY. The invention also provides compositions and methods useful for controlling biological activities such as cell proliferation, nutrient transport, lipolysis, and intestinal water and electrolyte secretion. | 2010-12-30 |
20100331246 | ESTER-BASED INSULIN PRODRUGS - Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability. | 2010-12-30 |
20100331247 | PEPTIDE THERAPY FOR HYPERGLYCEMIA - Methods of modulating blood glucose levels treating hyperglycemia and related complications and conditions by administration of a VGF biomolecule to a patient in need of such treatment are provided. Methods of enhancing insulin secretion from islet beta cells in a mammal exhibiting reduced insulin secretion by administration of a therapeutically effective amount of a VGF biomolecule are also provided. | 2010-12-30 |
20100331248 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE AND ISLET NEOGENESIS ASSOCIATED PEPTIDE - Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring β-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline (LSF) is an immunomodulator that reduces cytokine signaling and reduces the onset of T1DM in non-obese diabetic (NOD) mice. A combination therapy with both LSF (pretreatment) and INGAP provides protection from autoimmune destruction. The concomitant or combination of LSF and INGAP after pre-treatment with LSF is an effective therapy for a disease or condition resulting from the loss of pancreatic islet cells or insulin production in a mammal. | 2010-12-30 |
20100331249 | Pharmaceutical composition for inhibiting peritoneal dissemination - A pharmaceutical composition for treating or preventing peritoneal dissemination is provided. The pharmaceutical composition includes an effective dose of connective tissue growth factor (CTGF) and an acceptable receptor thereof. | 2010-12-30 |
20100331250 | ANTI-ANGIOGENESIS FUSION PROTEINS - The disclosure provides a novel anti-angiogenesis fusion protein. The present invention combines a chimeric vascular endothelial cell growth factor (VEGF) receptor or a fragment thereof with a multimerizing component, which have a superior binding capacity with human VEGF and placental growth factor (PIGF). The fusion protein has improved stability, prolonged half-life and the ability to form multivalent interactions with VEGF, and can be used for anti-angiogenesis, treating VEGF related diseases and inhibiting tumor growth. | 2010-12-30 |
20100331251 | POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1 - The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue. | 2010-12-30 |
20100331252 | Myostatin inhibitor enhancement of musculoskeletal repair - The methods and compositions of this invention provide a means of regenerating injured musculoskeletal tissue by inhibition of myostatin function. The invention provides methods of treating a nonunion fracture in an individual comprising delivering to the fracture via a delivery system comprising biodegradable hydrogel, a pharmacological amount of myostatin propeptide effective to inhibit myostatin function. The invention also teaches compositions useful for the treatment of non-union fracture in an individual, said compositions comprising a pharmacological amount of myostatin propeptide effective to inhibit myostatin function; and a delivery system for delivering said myostatin propeptide to said fracture, wherein the delivery system comprises a biodegradable hydrogel or biodegradable nanobeads. | 2010-12-30 |
20100331253 | METHOD FOR CELL ADHESION AND WOUND HEALING - The present invention relates to a method for cell adhesion and wound healing with internal domains of βig-h3. Particularly, the present invention relates to the method of using recombinant proteins comprising one or more of 2 | 2010-12-30 |
20100331254 | PULVERIZED FIBRIN CLOTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Provided is a pulverized fibrin clot and a pharmaceutical composition including a pulverized fibrin clot. The pharmaceutical composition may contain the pulverized fibrin clot suspended in a gel such as cross-linked hyaluronic acid. The pharmaceutical composition may be in a form suitable for injection and may be used, for example, in the treatment of connective tissue, such as skin connective tissue. Also provided is a method for preparing a pulverized fibrin clot as well as a method for treating connective tissue using the pharmaceutical composition. | 2010-12-30 |
20100331255 | Compositions and Methods for Increasing Production of Recombinant Gamma-Carboxylated Proteins - Methods and cell lines for overexpressing functional gamma-carboxylated proteins are disclosed by way of genetically engineered cell lines which over-express VKORC1. Also disclosed is the antisense inhibition of expression of calumenin in conjunction with overexpression of VKORC1 which also increases expression of functional gamma-carboxylated proteins. Gamma-carboxylated proteins of interest may include blood coagulation factors such as human clotting factors IX and VII. | 2010-12-30 |
20100331256 | Variants of C-Type Natriuretic Peptides - The present invention provides variants of C-type natriuretic peptide (CNP) comprising one or more deletions; additions of and/or substitutions with natural amino acids, unnatural amino acids and/or peptidomimetics (including peptide bond isosteres); amino acid extensions; and/or other chemical moieties such as, e.g., poly(ethylene glycol) and hydrophobic acids. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders such as, e.g., skeletal dysplasias and achondroplasia, and vascular smooth muscle disorders such as, e.g., restenosis and arteriosclerosis. | 2010-12-30 |
20100331257 | PREPARATION OF TERMINALLY-STERILIZED COLLAGEN THAT IS SOLUBLE AT NEUTRAL PH - Terminally sterilized collagen that is soluble at a neutral pH is useful for medical uses. The invention also relates to the method for preparing such terminally sterilized collagen. | 2010-12-30 |
20100331258 | MEMORY IN SUBJECTS WITH MINI-MENTAL STATE EXAMINATION OF 24-26 - The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and/or eicosapentaenoic acid, for improving memory and/or the treatment or prevention of impaired memory function, in a subject with a mini-mental state examination of 24-26, wherein said composition is enterally administered to the subject. In the MMSE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors' belief that within the group of 20-26, the memory impairment in the sub-group of 24-26 may even be reversible, as the pathological pathways have just started to develop. In this group of subjects the pathological pathways have just started to develop. Clinical studies show excellent results for this subgroup. | 2010-12-30 |
20100331259 | USE OF A NEUROTOXIC COMPONENT OF A CLOSTRIDIUM BOTULINUM TOXIN COMPLEX TO REDUCE OR PREVENT SIDE EFFECTS. - Use of a neurotoxic component of a | 2010-12-30 |
20100331260 | Stabilized bitamin c derivatives having a peptide molecule, preparation method thereof, and composition containing the same - The present invention relates to a stabilized vitamin C derivative with a peptide molecule linked to vitamin C or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a composition containing the same. | 2010-12-30 |
20100331261 | USE OF ALPHA-1-ANTITRYPSIN FOR THE PREPARATION OF DRUGS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME - The present invention relates to the use of alpha-1-antitrypsin for the preparation of effective drugs for the treatment of chronic fatigue syndrome. In addition, the present invention relates to the use of plasma or other therapeutic forms with an alpha-1-antitrypsin content sufficient to obtain a dose of 6 mg or more of alpha-1-antitrypsin per kg of body weight at a frequency of between 1 and 31 days. | 2010-12-30 |
20100331262 | PEPTIDE VACCINE USING MIMIC MOLECULES OF AMYLOID Beta PEPTIDE - This invention is intended to discover a peptide that induces production of an antibody specific for an abnormal amyloid β peptide from mimic peptides of the amyloid β peptide and to utilize the same as a vaccine or immunogen. This invention relates to a pharmaceutical composition containing a peptide consisting of 8 to 30 amino acid residues, wherein the peptide comprises at least one of an amino acid sequence represented by formula (I): Tyr-Gly-Thr-Lys-Pro-Trp-Met (SEQ ID NO: 28) (I), and an amino acid sequence represented by formula (II): Leu-Asp-Ile-Phe-Ala-Pro-Ile (SEQ ID NO: 29) (II); or a conjugate of such peptide and a carrier. | 2010-12-30 |
20100331263 | METHODS AND COMPOSITIONS FOR INHIBITING ANGIOGENESIS - The present invention relates to methods and compositions for modulating angiogenesis. In particular, the present invention relates to Pigment Epithelial-derived Factor (PEDF) fragments for use in modulating angiogenesis and treating angiogenesis mediated disease. | 2010-12-30 |
20100331264 | PRESERVING SECONDARY PEPTIDE STRUCTURE - A method of preserving the α-helix secondary structure of N-Acetyl-D-Asp-D-Trp-D-Phe-D-Lys-D-Ala-D-Phe-D-Tyr-D-Asp-D-Lys-D-Val-D-Ala-D-Glu-D-Lys-D-Phe-D-Lys-D-Glu-D-Ala-D-Phe-Amide or N-Acetyl-L-Asp-L-Trp-L-Phe-L-Lys-L-Ala-L-Phe-L-Tyr-L-Asp-L-Lys-L-Val-L-Ala-L-Glu-L-Lys-L-Phe-L-Lys-L-Glu-L-Ala-L-Phe-Amide and compositions comprising such peptides are disclosed. | 2010-12-30 |
20100331265 | METHODS FOR THE PREVENTION AND TREATMENT OF BURN INJURIES AND SECONDARY COMPLICATIONS - The disclosure relates to methods for treating a subject suffering from a burn injury or associated complications by administering to the subject an effective amount of an aromatic-cationic peptide. For example, a burn injury may be associated with distant pathophysiological effects, such as hypermetabolism, skeletal muscle dysfunction, and organ damage. The disclosure also relates to methods for protecting a subject from a burn injury by administering an effective amount of an aromatic-cationic peptide to a subject at risk of a burn injury. | 2010-12-30 |
20100331266 | ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS - Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. | 2010-12-30 |
20100331267 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES - The present invention relates to methods for treating α-synucleinopathies, methods for modulating of assembly, folding, accumulation, oligomerization, rate of aggregation, oligomerization and clearance of proteins of fragments comprising α-synuclein aggregates in a subject, by administering a medicament comprising a therapeutically effective amount of a cyclohexanehexyl derivative. More specifically, the invention provides medicaments comprising at least one cyclohexanehexyl derivative of formula (III) or (IV) useful in improving neuron, glia and oligodendrocyte function, for slowing the degeneration and death of neurons, glial cells and oligodendrocytes in the brain and treating synucleinopathies such as Parkinson's disease. These medicaments are formulated for oral and parenteral administration. Formulae (III), (IV). | 2010-12-30 |
20100331268 | Nitrated Lipids and Methods of Making and Using Thereof - Described herein are nitrated lipids and methods of making and using the nitrated lipids. | 2010-12-30 |
20100331269 | TRITERPENES DERIVATIVES AND USES THEREOF AS ANTITUMOR AGENTS OR ANTI-INFLAMMATORY AGENTS - A compound of formula (I): | 2010-12-30 |